%0 Journal Article
%T Advances in structure-based drug design targeting membrane protein markers in prostate cancer.
%A Batista-Silva JP
%A Gomes D
%A Sousa SF
%A Sousa Â
%A Passarinha LA
%J Drug Discov Today
%V 29
%N 9
%D 2024 Sep 3
%M 39103143
%F 8.369
%R 10.1016/j.drudis.2024.104130
%X Prostate cancer (PCa) is one of the leading cancers in men and the lack of suitable biomarkers or their modulators results in poor prognosis. Membrane proteins (MPs) have a crucial role in the development and progression of PCa and can be attractive therapeutic targets. However, experimental limitations in targeting MPs hinder effective biomarker and inhibitor discovery. To overcome this barrier, computational methods can yield structural insights and screen large libraries of compounds, accelerating lead identification and optimization. In this review, we examine current breakthroughs in computer-aided drug design (CADD), with emphasis on structure-based approaches targeting the most relevant membrane-bound PCa biomarkers.